Therapeutic Asset Ratings
123 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Acalabrutinib
Leukemia
Inhye Ahn
P1/2
CC
(41)
Atrovastain
Leukemia
Assiut University
P1/2
CC
(41)
bt02
Leukemia
Biotroy Therapeutics
P1/2
CC
(41)
Capecitabine
Leukemia
Memorial Sloan Kettering Cancer Center
P1/2
CC
(41)
Capivasertib
Leukemia
University of Chicago
P1/2
CC
(41)
gdx012
Leukemia
Takeda
P1/2
CC
(41)
Max-40279-01
Leukemia
Maxinovel Pty., Ltd.
P1/2
CC
(41)
Mezigdomide
Leukemia
Memorial Sloan Kettering Cancer Center
P1/2
CC
(41)
Mosunetuzumab
Leukemia
Inhye Ahn
P1/2
CC
(41)
MP0533
Leukemia
Molecular Partners AG
P1/2
CC
(41)
Neratinib
Leukemia
Memorial Sloan Kettering Cancer Center
P1/2
CC
(41)
Roginolisib
Leukemia
Jennifer R. Brown, MD, PhD
P1/2
CC
(41)
Scri-Car22V2
Leukemia
Seattle Children's Hospital
P1/2
CC
(41)
Tagraxofusp
Leukemia
Jacqueline Garcia, MD
P1/2
CC
(41)
TRASTUZUMAB
Leukemia
Memorial Sloan Kettering Cancer Center
P1/2
CC
(41)
Trastuzumab Emtansine
Leukemia
Memorial Sloan Kettering Cancer Center
P1/2
CC
(41)
Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells
Leukemia
Medical College of Wisconsin
P1
C
(37)
bg1805
Leukemia
Guangzhou Bio-gene Technology Co., Ltd
P1
C
(37)
bh-30236
Leukemia
BlossomHill Therapeutics
P1
C
(37)
cd19/cd22-bispecific car-t cells
Leukemia
Seattle Children's Hospital
P1
C
(37)
cd22 car-t
Leukemia
Stanford University
P1
C
(37)
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr
Leukemia
Fred Hutchinson Cancer Center
P1
C
(37)
cg009301 for
Leukemia
Cullgen (Shanghai),Inc
P1
C
(37)
Cytokine Induced Memory-Like Natural Killer Cells
Leukemia
Dana-Farber Cancer Institute
P1
C
(37)
Cytokine-Induced Memory-Like Natural Killer Cells
Leukemia
Dana-Farber Cancer Institute
P1
C
(37)
Showing 76 to 100 of 123 assets
Previous
Page 4 of 5
Next
